Revenue ($USD) : $1,697,100,000
R&D spend : $205,000,000
Employees : 3000
Fiscal year end : 12/31/2023
CEO : Jim Hollingshead

www.insulet.com

Insulet develops wearable automated insulin delivery devices. Its flagship Omnipod patch pump is one of the leaders in the market, with the latest version — the Omnipod 5 — growing in popularity through the 2024 integration with the Dexcom G7 continuous glucose monitor (CGM). The company picked up expanded FDA clearance for the type 2 population in August 2024, launching the offering immediately after. –SW